

Pembrolizumab KEYNOTE-177

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS


Quality of life



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-177

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers
Therapeutic Indication: First-line treatment of adults with MSI-H or dMMR mCRC
Experimental Arm: Pembrolizumab
Control Arm: ChT ((5-fluorouracil-based therapy with or without bevacizumab or cetuximab)

